[{"data":1,"prerenderedAt":362},["ShallowReactive",2],{"story-153323-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":56,"questions":57,"relatedArticles":82,"body_color":360,"card_color":361},"153323",null,"Gilead's $12.6B Oncology Acquisition Surge | Pharma Supply Chain & Healthcare Product Opportunities for Sellers","- Three major biotech acquisitions in 6 weeks signal accelerated cancer therapy commercialization; creates supply chain opportunities for medical device, diagnostic, and patient support product sellers in oncology ecosystem",[],[10,11,12,13,14,15,16,17,18,19,20,21,15,22,15,11,23,24,25,26,27,28,29,30,31,32,33,34,15,35,36,37,38,39,40,41,42,43,44,45,46,47,15,15,48,49,50,51,52,53,54,55],"https://static.law360news.com/images/law360_square_logo_2021.png","https://images.barrons.com/im-68327031?width=700&height=466","https://biostock.se/wp-content/uploads/2026/04/buy-768x432.webp","https://mb.cision.com/Public/87/4331441/b1ec39efdb88fe72_800x800ar.jpeg","https://img.hoodline.com/2026/4/gileads-dollar315-billion-tubulis-grab-puts-cambridge-outpost-in-the-spotlight-1.webp","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-04/07/2026-04-07T122420Z_3_LYNXMPEM360NU_RTROPTP_3_OURO-MEDICINES-M-A-GILEAD-SCIENCES.JPG","https://cdn.sanity.io/images/0vv8moc6/pharmexec/31520445c91e3dacf1a038ea8ed593ea2db884e9-1280x720.png?w=1280&max-h=720&fit=crop&auto=format","https://web-cdnprod.aa.com.tr/uploads/Contents/2026/04/07/thumbs_b_c_1c1dddcf54096fdfe3382dcf4a0f96c9.jpg","https://cms-cdn.lmu.de/media/newsroom-content-hub/photos/tubulis1_1_1_format_l.jpg","https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/business_deal_spree_cart_bills.jpeg","https://static.gurufocus.com/cdn-cgi/image/width=500,quality=100/logos/0C000007VR.png?20","https://www.akm.ru/upload/iblock/f9c/0f8fngfc485z14kksj327hn9arjz3nbp/II_farmatsevtika.png","https://endpoints.news/wp-content/uploads/2025/10/Tubulis-team-Dominik-Schumacher-tile1.jpg","https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/large_gilead_logo_resized_6aec13afef.jpg","https://www.reuters.com/resizer/v2/3HNFZNTBRRNPDCK24NUUN6YDSY.jpg?auth=75d52e220bdc6eb5781f665b6dc593e1ed73037d77cb3a3dc7d91ea8cd49ae19&width=1920&quality=80","https://images.wsj.net/im-20096020?width=700&height=467","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA20lGn3.img?w=768&h=432&m=6","https://cdn.benzinga.com/files/images/story/2026/04/07/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpeg?width=1200&height=800&fit=crop","https://bebeez.eu/wp-content/uploads/2023/05/BeBeezInt_PrivateEquity_473110270.jpg","https://www.statnews.com/wp-content/uploads/2024/08/GettyImages-1221879711-645x645.jpg","https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_1671396043-430x241.jpg","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://www.genengnews.com/wp-content/uploads/2026/04/Gilead-lab-shot-768x432-1.jpg","https://pharmaphorum.com/sites/default/files/styles/x_large/public/2026-04/Tubulis_Gilead_960x540.jpg?itok=BInk8m2H","https://insights.citeline.com/resizer/v2/XOCVJ5DTBNFBNHOF4NYFROFPOU.jpg?smart=true&auth=d4510a59dd2b27dcd3d73431463956264535b530967a8fb18df51b491c7dbec7&width=700&height=394","https://i.cdn.newsbytesapp.com/images/l144_10231775576776.jpg","https://nationaltoday.com/wp-content/uploads/not-wordpress/2026/04/69d595dd4298a.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA20mEBc.img?w=768&h=576&m=6","https://www.oncologypipeline.com/apexonco/sites/default/files/styles/large/public/articles/Gilead%20buliding.jpg","https://imgproxy.divecdn.com/skkaWlFhTDPMbfIXmqOuyBKuimuCXFjfagjcvWa7beA/g:nowe:0:0/c:5076:2867/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjIxODc5NzA5X2s2czFWcGkuanBn.webp","https://medcitynews.com/wp-content/uploads/sites/7/2020/12/GettyImages-1221884666-600x400.jpg","https://eu-images.contentstack.com/v3/assets/blt72fb3b8b4630b7db/bltf8739b46a8c91e5b/69d5273d75feea852f4f41a0/Depositphotos_143021785_L.jpg?width=1280&auto=webp&quality=80&format=jpg&disable=upscale","https://nationaltoday.com/wp-content/uploads/not-wordpress/2026/04/69d533b4c7de7.jpg","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1511179609.jpg?VersionId=._rw5NJ3iABUltZwmktyYANf6vwrcqkX","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-860534328.jpg?VersionId=Z53DOecNQ0ib8cKac8_V6SE.m7gPpuZ7","https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/ADC-illustration.webp?t=1763043550&width=800","https://media.bizj.us/view/img/12986277/gilead-5*900xx9469-5326-0-494.jpg","https://etimg.etb2bimg.com/thumb/msid-130099991,width-1200,height-900,resizemode-4/.jpg","https://cdn.sanity.io/images/0vv8moc6/biopharn/29f1e6f63b2a5a331dd153d454f6879a0aa8733b-1280x720.jpg","https://static.biospace.com/dims4/default/ea7b3dc/2147483647/strip/true/crop/1254x706+0+65/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2F41%2Ff0%2F532064374b92b3cb5bbdc6e7770a%2Fistock-468340908.jpg","https://nationaltoday.com/wp-content/uploads/not-wordpress/2026/04/69d54a0d8635b.jpg","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-07-04T140834Z_1_LYNXMPEL630MD_RTROPTP_3_USA-STOCKS.JPG","https://d3t5t78xsxj5vn.cloudfront.net/Pictures/2000xAny/3/7/8/20378_shutterstock_2689037929_488826.jpg","https://european-biotechnology.com/wp-content/uploads/2024/07/tubulis_linker_ADC_web.jpg","https://www.bnnbloomberg.ca/resizer/v2/7SB3EP2WKQ5JLKTQZJVM626Y34.jpg?auth=9361a7ba4d45ddaa8c4cd62e73cdd3de6319d54d4f47579b44a8cbe7a4c928e5","Gilead Sciences' aggressive $12.6 billion acquisition strategy—acquiring CAR-T specialist Arcellx ($7.8B in February), T-cell engager biotech Ouro Medicines ($1.67B in March), and ADC platform company Tubulis ($3.15B in April 2026)—represents a fundamental reshaping of the pharmaceutical innovation landscape with significant indirect implications for cross-border e-commerce sellers. CEO Daniel O'Day's pivot from M&A to integration signals that Gilead is consolidating complementary technologies to accelerate time-to-market for next-generation cancer therapies, creating a 24-36 month window of heightened clinical trial activity, regulatory submissions, and commercialization infrastructure buildout.\n\n**Supply Chain and Product Opportunities**: The acquisition of Tubulis' novel ADC linker technology (P5 and Alco5 platforms) and the planned 2027 registrational trial for OM336 indicate Gilead will require expanded manufacturing, cold-chain logistics, patient support services, and diagnostic companion products. E-commerce sellers can capitalize on this through: (1) Medical device and diagnostic test kit distribution to clinical trial sites across Europe and North America; (2) Patient support products (nausea management, immune system support supplements) targeting multiple myeloma and ovarian cancer patient communities; (3) Specialized packaging and shipping solutions for temperature-controlled pharmaceutical samples; (4) Healthcare professional training materials and certification courses on new therapy protocols.\n\n**Market Consolidation and Competitive Dynamics**: The strategy of converting existing partnerships (Ouro and Tubulis were prior collaborators) into full acquisitions demonstrates Gilead's confidence in these platforms' commercial potential. This consolidation reduces the number of independent biotech players in oncology, potentially creating supply chain bottlenecks for smaller competitors and opening opportunities for sellers to position as alternative suppliers of complementary products. The Munich-based Tubulis unit's continued operation signals European manufacturing expansion, creating logistics opportunities for sellers serving German and EU pharmaceutical distribution networks.\n\n**Regulatory and Timeline Implications**: With anito-cel awaiting FDA approval for multiple myeloma and OM336 launching registrational trials in 2027, sellers should anticipate 18-24 months of accelerated demand for clinical trial support products, patient recruitment services, and post-approval commercialization infrastructure. The Belgian partnership with Galapagos (contributing 50% of Ouro acquisition cost) indicates multi-country regulatory coordination, creating opportunities for sellers with EU distribution capabilities.",[58,61,64,67,70,73,76,79],{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"How does FDA approval timeline for anito-cel affect seller opportunities?","Anito-cel's pending FDA approval for multiple myeloma creates immediate opportunities for sellers to develop post-approval commercialization support products. The approval timeline typically spans 12-24 months from submission, creating windows for sellers to: (1) develop patient education and disease awareness materials; (2) establish relationships with oncology clinics and treatment centers; (3) create patient support programs addressing CAR-T therapy side effects; (4) develop diagnostic companion products for patient selection and monitoring. Sellers should monitor FDA approval announcements and establish distribution partnerships with major cancer treatment centers 6-12 months before anticipated approval to capture early commercialization demand.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"What manufacturing and logistics implications emerge from Gilead's three acquisitions?","The three acquisitions require integrated manufacturing, quality control, and distribution infrastructure for CAR-T therapies, T-cell engagers, and ADC platforms. Sellers should anticipate demand for: (1) specialized manufacturing equipment and consumables for cell therapy production; (2) cold-chain logistics solutions for temperature-sensitive biologics; (3) regulatory compliance and quality assurance services; (4) clinical trial logistics and patient recruitment support. The commitment to maintaining acquired teams and Tubulis' Munich-based operations signals European manufacturing expansion, creating opportunities for sellers with German and EU pharmaceutical distribution networks and cold-chain capabilities.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"What regional opportunities exist from Gilead's multi-country partnership strategy?","Gilead's Belgian partnership with Galapagos (contributing 50% of Ouro acquisition cost) and Tubulis' Munich-based operations indicate strong European regulatory focus and manufacturing expansion. Sellers with EU distribution capabilities, regulatory expertise, and established relationships in European clinical research networks have competitive advantages. The multi-country strategy suggests coordinated regulatory submissions across North America and Europe, creating 24-36 month windows for sellers to establish distribution partnerships, develop localized patient support products, and position themselves in European pharmaceutical supply chains. Sellers should prioritize EU regulatory compliance, cold-chain logistics capabilities, and relationships with European clinical research organizations.",{"title":68,"answer":69,"author":5,"avatar":5,"time":5},"How does Gilead's $12.6B acquisition strategy create opportunities for e-commerce sellers?","Gilead's rapid consolidation of three complementary oncology platforms (CAR-T, T-cell engagers, and ADC technology) accelerates the commercialization timeline for next-generation cancer therapies, creating 24-36 months of heightened demand for clinical trial support products, patient diagnostics, and specialized logistics services. E-commerce sellers can target clinical research organizations, hospital networks, and patient support communities with medical devices, diagnostic kits, and patient education materials. The planned 2027 registrational trial for OM336 and FDA approval pathway for anito-cel signal specific windows for sellers to position complementary products in oncology supply chains across North America and Europe.",{"title":71,"answer":72,"author":5,"avatar":5,"time":5},"How does the Ouro Medicines acquisition impact patient support product demand?","Ouro's OM336 (gamgertamig) targets autoimmune conditions through immune system resetting, with registrational trials launching as early as 2027. This creates demand for patient support products addressing immune-related side effects, including nausea management supplements, immune system support formulations, and patient education materials. Sellers can develop and distribute complementary products targeting the autoimmune patient community, particularly in Europe where Belgian partner Galapagos contributes 50% of acquisition costs, indicating strong EU regulatory focus. The 2027 trial timeline provides 12-18 months for sellers to establish distribution partnerships with clinical trial sites and patient advocacy organizations.",{"title":74,"answer":75,"author":5,"avatar":5,"time":5},"What supply chain opportunities emerge from Tubulis' ADC linker technology acquisition?","Tubulis' novel P5 and Alco5 linker platforms enable new payload classes for antibody-drug conjugates, requiring expanded manufacturing, quality control, and cold-chain logistics infrastructure. Sellers can capitalize through: (1) specialized temperature-controlled packaging solutions for ADC manufacturing samples; (2) laboratory equipment and consumables for payload development; (3) regulatory compliance documentation and training services for manufacturing partners; (4) distribution services to clinical trial sites in Europe and North America. The Munich-based Tubulis unit's continued operation creates specific opportunities for sellers with German and EU pharmaceutical logistics capabilities.",{"title":77,"answer":78,"author":5,"avatar":5,"time":5},"How should sellers prepare for the 2027 OM336 registrational trial launch?","The planned 2027 registrational trial for OM336 creates a 12-18 month preparation window for sellers to establish distribution partnerships, develop complementary products, and position themselves in clinical trial supply chains. Sellers should: (1) identify clinical research organizations and hospital networks participating in trial sites; (2) develop patient support products addressing autoimmune condition management; (3) establish cold-chain logistics capabilities for trial sample distribution; (4) create regulatory compliance documentation for EU and North American markets. The Belgian partnership with Galapagos indicates strong European focus, making EU distribution capabilities and regulatory expertise critical competitive advantages.",{"title":80,"answer":81,"author":5,"avatar":5,"time":5},"What competitive advantages do sellers gain from Gilead's partnership-to-acquisition strategy?","Gilead's conversion of existing collaborations (Ouro and Tubulis) into full acquisitions demonstrates confidence in these platforms' commercial potential and reduces the number of independent biotech players in oncology. This consolidation creates supply chain bottlenecks for smaller competitors, opening opportunities for sellers to position as alternative suppliers of complementary products. Sellers with established relationships in clinical research, diagnostic testing, or patient support can differentiate by offering integrated solutions that address gaps created by Gilead's internal consolidation, particularly in European markets where regulatory coordination with Galapagos indicates multi-country expansion.",[83,88,92,97,101,106,111,116,119,124,128,132,137,141,145,149,153,157,160,164,168,172,175,179,183,188,192,197,201,205,209,213,217,221,224,228,232,236,240,243,246,249,253,257,261,265,269,273,277,281,285,289,293,297,301,305,309,313,317,320,324,328,332,336,340,344,349,352,356],{"id":84,"title":85,"source":86,"logo":15,"time":87},715440,"Gilead to buy Germany’s Tubulis for up to $5 billion to boost cancer pipeline","https://kelo.com/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-5-billion-to-boost-cancer-pipeline/","1D AGO",{"id":89,"title":90,"source":91,"logo":5,"time":87},710874,"Gilead to acquire Tubulis GmbH for up to $5 billion","https://finance.yahoo.com/sectors/healthcare/articles/gilead-acquire-tubulis-gmbh-5-122420393.html",{"id":93,"title":94,"source":95,"logo":45,"time":96},713980,"With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'","https://www.fiercebiotech.com/biotech/3-new-acquisitions-digest-gilead-shifts-focus-pipeline-has-never-been-stronger","12H AGO",{"id":98,"title":99,"source":100,"logo":13,"time":87},709928,"EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion","https://news.cision.com/eqt/r/eqt-life-sciences-to-exit-minority-stake-in-tubulis-via-sale-to-gilead-sciences-for-up-to-usd-5-0-bi,c4331441",{"id":102,"title":103,"source":104,"logo":5,"time":105},713776,"Gilead Acquires Tubulis to Expand ADC Capabilities","https://intellectia.ai/news/stock/gilead-acquires-tubulis-to-expand-adc-capabilities","19H AGO",{"id":107,"title":108,"source":109,"logo":53,"time":110},715437,"Gilead strengthens ADC capabilities with $5bn Tubulis acquisition","https://www.europeanpharmaceuticalreview.com/gilead-strengthens-adc-capabilities-with-5bn-tubulis-acquisition/2135147.article","10H AGO",{"id":112,"title":113,"source":114,"logo":48,"time":115},713775,"Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline","https://pharma.economictimes.indiatimes.com/news/mergers-and-acquisitions/gilead-to-buy-germanys-tubulis-for-up-to-5-billion-to-boost-cancer-pipeline/130099991","17H AGO",{"id":117,"title":85,"source":118,"logo":15,"time":87},713778,"https://kfgo.com/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-5-billion-to-boost-cancer-pipeline/",{"id":120,"title":121,"source":122,"logo":18,"time":123},715439,"Successful research transfer: US corporation Gilead acquires LMU spin-off Tubulis","https://www.lmu.de/en/newsroom/news-overview/news/successful-research-transfer-us-corporation-gilead-acquires-lmu-spin-off-tubulis-58756fcd.html","11H AGO",{"id":125,"title":85,"source":126,"logo":15,"time":127},713777,"https://wincountry.com/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-5-billion-to-boost-cancer-pipeline/","23H AGO",{"id":129,"title":130,"source":131,"logo":19,"time":110},715438,"Gilead Tubulis Deal Expands ADC Oncology Pipeline And Valuation Debate","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-tubulis-deal-expands-adc-oncology-pipeline-and-valuat",{"id":133,"title":134,"source":135,"logo":38,"time":136},713774,"Gilead-Tubulis $5B deal gives STRO stock a boost — here’s why","https://www.msn.com/en-us/money/topstocks/gilead-tubulis-5b-deal-gives-stro-stock-a-boost-here-s-why/ar-AA20mYBF","16H AGO",{"id":138,"title":139,"source":140,"logo":5,"time":96},713773,"Gilead's Stock Price is Expected to Rise to $160，Gilead’s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America","https://www.tradingkey.com/analysis/stocks/us-stocks/261760421-gilead-stock-price-160-5-billion-tubulis-cancer-drug-market-tradingkey",{"id":142,"title":143,"source":144,"logo":40,"time":87},709933,"Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis","https://www.biopharmadive.com/news/gilead-tubulis-acquire-deal-adc-cancer/816823/",{"id":146,"title":147,"source":148,"logo":12,"time":87},710889,"Gilead strengthens oncology portfolio with multibillion-dollar acquisition of Tubulis","https://www.biostock.se/en/2026/04/gilead-starker-onkologiportfoljen-genom-miljardforvarv-av-tubulis/",{"id":150,"title":151,"source":152,"logo":42,"time":87},709932,"Gilead expands ADC capabilities with $5bn Tubulis buy","https://www.bioxconomy.com/partnering/gilead-expands-antibody-conjugate-capabilities-with-5bn-tubulis-buy",{"id":154,"title":155,"source":156,"logo":10,"time":87},710888,"5 Firms Advise On Gilead's Up To $5B Tubulis Acquisition","https://www.law360.com/articles/2462286/5-firms-advise-on-gilead-s-up-to-5b-tubulis-acquisition",{"id":158,"title":99,"source":159,"logo":29,"time":87},709935,"https://bebeez.eu/2026/04/07/eqt-life-sciences-to-exit-minority-stake-in-tubulis-via-sale-to-gilead-sciences-for-up-to-usd-5-0-billion/",{"id":161,"title":162,"source":163,"logo":11,"time":87},710887,"Gilead to Buy German Biotech Tubulis for Up to $5 Billion. The Stock Falls.","https://www.barrons.com/articles/gilead-stock-tubulis-acquisition-cancer-32bee850?gaa_at=eafs&gaa_n=AWEtsqdVDXM-fi7L5Ifc-YIEPYR4vZPeMcPUBtD75O4JZTqfCSxzq9xsJJCX&gaa_ts=69d56709&gaa_sig=QNrIdZ_ydvbQWVEt9MQcTHIkngDzrzlX4mcxz4KiJlWqSJXC2WUsRDBcbvmgJ0TYxsWU3XGTDFbzOWiRLFF30g%3D%3D",{"id":165,"title":166,"source":167,"logo":54,"time":87},709934,"Andera Partners-backed Tubulis from Munich snapped up by Gilead Sciences in multi-billion dollar ADC deal","https://european-biotechnology.com/latest-news/andera-partners-backed-tubulis-from-munich-snapped-up-by-gilead-sciences-in-multi-billion-dollar-adc-deal/",{"id":169,"title":170,"source":171,"logo":47,"time":87},710886,"Cambridge biotech bought by Gilead for $3.15B","https://www.bizjournals.com/boston/news/2026/04/07/german-cambridge-biotech-bought-by.html",{"id":173,"title":113,"source":174,"logo":25,"time":87},709937,"https://www.reuters.com/legal/transactional/gilead-acquire-tubulis-gmbh-up-5-billion-2026-04-07/",{"id":176,"title":177,"source":178,"logo":27,"time":87},709936,"Market Open: Gilead Buys Tubulis, Universal Music Soars on Takeover Bid | Apr 7th","https://www.msn.com/en-ca/money/topstories/market-open-gilead-buys-tubulis-universal-music-soars-on-takeover-bid-apr-7th/ar-AA20lJ0C",{"id":180,"title":181,"source":182,"logo":17,"time":87},709939,"US pharma firm Gilead to acquire German biotech company Tubulis to boost cancer pipeline","https://www.aa.com.tr/en/economy/us-pharma-firm-gilead-to-acquire-german-biotech-company-tubulis-to-boost-cancer-pipeline/3896398",{"id":184,"title":185,"source":186,"logo":37,"time":187},712868,"Gilead Sciences Expands Pipeline with Tubulis, Ouro, and Arcellx Deals","https://nationaltoday.com/us/ca/foster-city/news/2026/04/07/gilead-sciences-expands-pipeline-with-tubulis-ouro-and-arcellx-deals/","20H AGO",{"id":189,"title":190,"source":191,"logo":31,"time":87},709938,"Gilead outlays $5bn to acquire ADC specialist Tubulis","https://www.pharmaceutical-technology.com/news/gilead-outlays-5bn-to-acquire-adc-specialist-tubulis/",{"id":193,"title":194,"source":195,"logo":5,"time":196},712869,"GILD: Three strategic acquisitions add best-in-class assets and platforms, fueling long-term growth","https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3230665:0-gild-three-strategic-acquisitions-add-best-in-class-assets-and-platforms-fueling-long-term-growth/","21H AGO",{"id":198,"title":199,"source":200,"logo":44,"time":87},709973,"Gilead pays $3.1B for Tubulis to bolster oncology ADC pipeline","https://www.fiercebiotech.com/biotech/gilead-inks-5b-tubulis-buyout-bolster-oncology-adc-pipeline",{"id":202,"title":203,"source":204,"logo":5,"time":87},709972,"Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline","https://www.businesswire.com/news/home/20260406252364/en/Gilead-to-Acquire-Tubulis-Adding-Potentially-Best-in-Class-Antibody-Drug-Conjugate-and-Next-Generation-Platform-to-Further-Strengthen-Oncology-Pipeline",{"id":206,"title":207,"source":208,"logo":5,"time":87},709931,"Gilead Sciences to Buy Tubulis for Up to $5 Billion, Bloomberg Reports","https://www.moomoo.com/news/post/67973326/gilead-sciences-to-buy-tubulis-for-up-to-5-billion",{"id":210,"title":211,"source":212,"logo":32,"time":87},709930,"Gilead Sciences To Acquire Tubulis GmbH","https://www.tradingview.com/news/reuters.com,2026:newsml_P8N3W407W:0-gilead-sciences-to-acquire-tubulis-gmbh/",{"id":214,"title":215,"source":216,"logo":23,"time":87},709974,"Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs","https://endpoints.news/gilead-continues-dealmaking-streak-with-3-15b-tubulis-buy-for-adcs/",{"id":218,"title":219,"source":220,"logo":28,"time":87},712190,"Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal","https://www.benzinga.com/m-a/26/04/51685029/gilead-acquisition-spree-continues-with-3-billion-tubulis-deal",{"id":222,"title":155,"source":223,"logo":5,"time":87},712191,"https://www.law360.com/healthcare-authority/articles/2462286/5-firms-advise-on-gilead-s-up-to-5b-tubulis-acquisition",{"id":225,"title":226,"source":227,"logo":26,"time":87},710892,"Gilead to Buy German Biotech Tubulis for $3 Billion for Experimental Cancer Drugs","https://www.wsj.com/tech/biotech/gilead-sciences-to-buy-clinical-stage-biotech-tubulis-for-up-to-5-billion-2a829f4e?gaa_at=eafs&gaa_n=AWEtsqds45PEkB05Lz-dDHkE2PKjlKx7pJPIwmgglZRvO9igN4OqDSCshtpU&gaa_ts=69d56709&gaa_sig=BmDGtlWhPVWai6cJ5A2gk1O7Qvc_LhMKdtjWgmm6PAfmkG_9A7cAmXkOjD3I9UKyS0K6KeJy6eCG6zPquIJymA%3D%3D",{"id":229,"title":230,"source":231,"logo":30,"time":87},709929,"Gilead to buy cancer biotech Tubulis for more than $3 billion","https://www.statnews.com/2026/04/07/gilead-sciences-acquisition-tubulis-adcs-chemotherapy-cancer/",{"id":233,"title":234,"source":235,"logo":5,"time":87},710891,"Gilead to acquire Tubulis for $3.15 billion upfront","https://www.investing.com/news/company-news/gilead-to-acquire-tubulis-for-315-billion-upfront-93CH-4600713",{"id":237,"title":238,"source":239,"logo":39,"time":87},710890,"Gilead buys what it tried with Tubulis | ApexOnco - Clinical Trials news and analysis","https://www.oncologypipeline.com/apexonco/gilead-buys-what-it-tried-tubulis",{"id":241,"title":85,"source":242,"logo":15,"time":87},712870,"https://wtvbam.com/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-5-billion-to-boost-cancer-pipeline/",{"id":244,"title":85,"source":245,"logo":15,"time":87},712871,"https://wsau.com/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-5-billion-to-boost-cancer-pipeline/",{"id":247,"title":85,"source":248,"logo":15,"time":87},712872,"https://whtc.com/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-5-billion-to-boost-cancer-pipeline/",{"id":250,"title":251,"source":252,"logo":5,"time":87},709944,"Gilead to acquire Tubulis for $3.15 billion upfront By Investing.com","https://in.investing.com/news/company-news/gilead-to-acquire-tubulis-for-315-billion-upfront-93CH-5325934",{"id":254,"title":255,"source":256,"logo":51,"time":87},710878,"Gilead to Acquire Tubulis, Expanding Antibody-Drug Conjugate Portfolio","https://nationaltoday.com/us/ca/foster-city/news/2026/04/07/gilead-to-acquire-tubulis-expanding-antibody-drug-conjugate-portfolio/",{"id":258,"title":259,"source":260,"logo":16,"time":87},709943,"Gilead Enters $5 Billion Agreement to Acquire Tubulis","https://www.pharmexec.com/view/gilead-enters-5-billion-agreement-acquire-tubulis",{"id":262,"title":263,"source":264,"logo":5,"time":87},710877,"Gilead Sciences Is Betting on a Bavarian Biotech For Its Comeback","https://finance.yahoo.com/sectors/healthcare/articles/gilead-sciences-betting-bavarian-biotech-192112315.html",{"id":266,"title":267,"source":268,"logo":24,"time":87},710876,"Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why","https://stocktwits.com/news-articles/markets/equity/gilead-tubulis-5b-deal-gives-stro-stock-a-boost-here-why/cZJBRoxRIqc",{"id":270,"title":271,"source":272,"logo":14,"time":87},710875,"Gilead’s $3.15 Billion Tubulis Grab Puts Cambridge Outpost In The Spotlight","https://hoodline.com/2026/04/gilead-s-3-15-billion-tubulis-grab-puts-cambridge-outpost-in-the-spotlight/",{"id":274,"title":275,"source":276,"logo":35,"time":87},710879,"Gilead’s 2026 Shopping Spree Continues With Tubulis Buyout","https://insights.citeline.com/scrip/scrip/business/deals/gileads-2026-shopping-spree-continues-with-tubulis-buyout-YU5GFZBIMNF5HP4P2FFJPS2J6A/",{"id":278,"title":279,"source":280,"logo":50,"time":87},709940,"Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis","https://www.biospace.com/business/gilead-swallows-another-partner-paying-up-to-5-b-for-adc-specialist-tubulis",{"id":282,"title":283,"source":284,"logo":5,"time":87},709942,"Gilead Sciences (GILD) Expands Cancer Pipeline With $5 Billion Tubulis Acquisition","https://coincentral.com/gilead-sciences-gild-expands-cancer-pipeline-with-5-billion-tubulis-acquisition/",{"id":286,"title":287,"source":288,"logo":34,"time":87},709941,"Gilead strikes again, penning $5bn deal to buy Tubulis","https://pharmaphorum.com/news/gilead-strikes-again-penning-5bn-deal-buy-tubulis",{"id":290,"title":291,"source":292,"logo":41,"time":87},712183,"Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis","https://medcitynews.com/2026/04/gilead-sciences-tubulis-acquisition-ovarian-cancer-antibody-drug-conjugate-adc-gild/",{"id":294,"title":295,"source":296,"logo":22,"time":87},712184,"American biopharmaceutical company Gilead acquires German Tubulis for $5 billion","https://www.akm.ru/eng/news/american-biopharmaceutical-company-gilead-acquires-german-tubulis-for-5-billion/",{"id":298,"title":299,"source":300,"logo":5,"time":87},712185,"Leerink sees Gilead’s $5B Tubulis buy as ‘more than an oncology bolt-on’","https://www.tipranks.com/news/the-fly/leerink-sees-gileads-5b-tubulis-buy-as-more-than-an-oncology-bolt-on-thefly-news",{"id":302,"title":303,"source":304,"logo":55,"time":87},712186,"Gilead to buy Germany’s Tubulis for up to US$5 billion to boost cancer pipeline","https://www.bnnbloomberg.ca/business/2026/04/07/gilead-to-buy-germanys-tubulis-for-up-to-us5-billion-to-boost-cancer-pipeline/",{"id":306,"title":307,"source":308,"logo":36,"time":87},710881,"Gilead Sciences to buy Germany's Tubulis for up to $5B","https://www.newsbytesapp.com/news/business/gilead-sciences-to-buy-germanys-tubulis-for-up-to-5b/tldr",{"id":310,"title":311,"source":312,"logo":5,"time":87},712147,"GILD: Acquisitions of Tubulis, Ouro, and Arcellx drive pipeline growth and market expansion","https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3230520:0-gild-acquisitions-of-tubulis-ouro-and-arcellx-drive-pipeline-growth-and-market-expansion/",{"id":314,"title":315,"source":316,"logo":21,"time":87},710880,"Gilead (GILD) to Acquire Tubulis, Strengthening Antibody-Drug Co","https://www.gurufocus.com/news/8779510/gilead-gild-to-acquire-tubulis-strengthening-antibodydrug-conjugate-position",{"id":318,"title":315,"source":319,"logo":5,"time":87},712148,"https://www.gurufocus.com/news/8779510/gilead-gild-to-acquire-tubulis-strengthening-antibodydrug-conjugate-position?mobile=true",{"id":321,"title":322,"source":323,"logo":5,"time":87},710885,"Evotec (NASDAQ: EVO) eyes $100M Tubulis payout and new board chairman","https://www.stocktitan.net/sec-filings/EVO/6-k-evotec-se-current-report-foreign-issuer-260ae3beef71.html",{"id":325,"title":326,"source":327,"logo":49,"time":87},712187,"Gilead Buys Tubulis to Boost ADC Platform","https://www.biopharminternational.com/view/gilead-buys-tubulis-to-boost-adc-platform",{"id":329,"title":330,"source":331,"logo":20,"time":87},710884,"Gilead's deal spree rolls on with Tubulis takeover for up to $5B","https://firstwordpharma.com/story/7172952",{"id":333,"title":334,"source":335,"logo":5,"time":196},712144,"Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom","https://finance.yahoo.com/sectors/healthcare/articles/gilead-sciences-details-tubulis-ouro-230856225.html",{"id":337,"title":338,"source":339,"logo":52,"time":87},712188,"Gilead Sciences, Inc. entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.","https://www.marketscreener.com/news/gilead-sciences-inc-entered-into-a-definitive-agreement-to-acquire-tubulis-gmbh-from-a-group-of-sh-ce7e51d3d08aff20",{"id":341,"title":342,"source":343,"logo":33,"time":87},710883,"Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities","https://www.genengnews.com/topics/cancer/gilead-to-acquire-tubulis-for-up-to-5b-expanding-cancer-adc-capabilities/",{"id":345,"title":346,"source":347,"logo":5,"time":348},712145,"GILD: Acquisitions of Tubulis, Ouro, and Arcellx add best-in-class assets and platforms for sustained growth","https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3230635:0-gild-acquisitions-of-tubulis-ouro-and-arcellx-add-best-in-class-assets-and-platforms-for-sustained-growth/","22H AGO",{"id":350,"title":162,"source":351,"logo":11,"time":87},712189,"https://www.barrons.com/articles/gilead-stock-tubulis-acquisition-cancer-32bee850",{"id":353,"title":354,"source":355,"logo":43,"time":87},710882,"Gilead Sciences Acquires Tubulis for $3 Billion","https://nationaltoday.com/us/ca/foster-city/news/2026/04/07/gilead-sciences-acquires-tubulis-for-3-billion/",{"id":357,"title":358,"source":359,"logo":46,"time":127},712146,"Gilead buying Tubulis and its ADCs in $5B takeover bid","https://www.bioworld.com/articles/730133-gilead-buying-tubulis-and-its-adcs-in-5b-takeover-bid","#3c5a91ff","#3c5a914d",1775694656536]